Contribution of Immunohistochemical Profile in Assessing Histological Grade of Endometrial Cancer
- GEOFFROY CANLORBE1,2,
- ENORA LAAS1,2,
- SOFIANE BENDIFALLAH1,2,
- EMILE DARAÏ1,2,3 and
- MARCOS BALLESTER1,2,4⇑
- 1Departement of Obstetrics and Gynecology, Tenon University Hospital, APHP, Paris, France
- 2Institut Universitaire de Cancérologie, Université Pierre et Marie Curie, Paris, France
- 3UMRS 938, Université Pierre et Marie Curie, Paris, France
- 4ER2 UPMC, Université Pierre et Marie Curie, Paris, France
- Correspondence to: Marcos Ballester, MD, Departement of Obstetrics and Gynecology, Tenon University Hospital, APHP, Paris, France. Tel: +33 156016007, e-mail: marcos.ballester{at}tnn.aphp.fr
Abstract
Background: The aim of this study was to correlate immunostaining expression profiles with histological grade using a predictive model. Patients and Methods: Samples were collected from 69 women with endometrial cancer. Immunostaining for expression of estrogen receptor (ER), progesteron receptor (PR), Ki67 and p53 in grade 1 or 2 and grade 3 tumors were compared. After determining optimal immunostaining cut-offs, we built a model to predict the final histological grade. Results: Higher immunostaining of ER and PR was found in grade 1 or 2 (p=0.01) compared with grade 3 tumors. Higher immunostaining for Ki67 (p<0.0001) and p53 (p<0.001) was found in grade 3 than in grade 1 or 2 tumors. The recursive partitioning model predicted a grade 1 or 2 tumor in 98% of cases when Ki67 and p53 were underexpressed. The mis-classification rate was 13%. Conclusion: Our results show that integrating immunohistochemical profiles in a simple predictive model could help predict the final histological grade of endometrial tumors, especially for grade 1 or 2.
- Endometrial cancer
- immunohistochemistry
- histological grade
- estrogen receptor
- progesteron receptor
- Ki67
- p53
- predictive model
- Received February 16, 2013.
- Revision received March 20, 2013.
- Accepted March 21, 2013.
- Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved







